Boston Partners Adds $20M in Quest Diagnostics Incorporated ($DGX)
Key Points
- Boston Partners changed its Quest Diagnostics Incorporated ($DGX) stake by 2.5% last quarter, boosting to 4,012,232 shares worth $817.81 million.
- Wall Street's consensus rating on $DGX is Buy and an average price target of $223.44.
- $DGX last traded around $203.83.
Boston Partners increased its position in Quest Diagnostics Incorporated ($DGX) by 2.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,012,232 shares of Quest Diagnostics Incorporated after buying 98,906 shares during the quarter. Boston Partners's holdings in Quest Diagnostics Incorporated were worth $817.81 million as of its most recent filing.
Quest Diagnostics Incorporated ($DGX) Stock
Quest Diagnostics Incorporated Earnings
Quest Diagnostics Incorporated Dividend
Analysts Set New Price Targets
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.